The rapid evolution of artificial intelligence (AI) in the pharmaceutical and medical device (MD) sectors hasprompted interest in its potential role in supporting health technology assessment (HTA). This editorial presentsan innovative project aimed at facilitating and expanding HTA activities for high-risk MDs (Class IIb–III) in Italy,where structured HTA processes for MDs are inconsistently implemented. The project centers on a freely accessibleAI-based web tool designed to generate preliminary mini-HTA reports. The tool operates through twosteps: users provide essential device information via an online form, and ChatGPT produces a structured draft report, including PICO statements, coverage of the nine EUnetHTA domains, and a preliminary summary of relevantPubMed evidence. Although these AI-generated reports are imperfect and require expert verification and refinement, they offer substantial practical advantages by reducing the initial workload and enabling rapid production of a first draft—within minutes rather than hours. The project includes detailed operational instructions and real application examples, such as an artificial iris device, presented in supplementary appendices. Future developments include the release of an English-language version to support broader international use. While AI cannot replace expert judgment, the editorial highlights its value as an accelerative tool that can streamline early HTA steps and promote more systematic evaluation of MDs across Italian regions. Continued iterative use is expected to improve system performance and enhance integration into HTA workflows.
Messori et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: